Search clinical trials for: BMS-708163

Total 3150 results

University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)

Kidney Neoplasms

India
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Healthy Adult Normals

United States
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Pan Tumor

United States, Puerto Rico, Italy, Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Netherlands, Poland, Romania, Singapore, Spain, United Kingdom
Bristol-Myers Squibb
Yale University

Completed

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate 592)

Non-Small Cell Lung Cancer

Belgium, Italy, United States, France, Germany, Netherlands, Spain, Romania
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)

Renal Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostrate Cancer

United States
Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States, France, Netherlands, Australia, United Kingdom, Italy, Spain, Germany
Bristol-Myers Squibb

Terminated

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Cancer

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

HIV Infections

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Melanoma (Skin)

United States
Hackensack Meridian Health

Terminated

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)

Acute Myeloid Leukemia and Myelodysplastic Syndrome

United States
Boston Scientific Corporation

Completed

PROPPER Prospective Registry of Outcomes With Penile Prosthesis (PROPPER)

Erectile Dysfunction | Impotence

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Lupus

United Kingdom
Mansoura University

Unknown

Effect of Gastric Balloon in Morbid Obesity: Prospective Study

Morbid Obesity

Egypt
R-Pharm

Completed

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Metastatic Breast Cancer
JIANYANG WANG
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients

Esophageal Cancer | Thrombocytopenia | Concurrent Chemoradiotherapy | Intensity-modulated Radiation Therapy

China
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Healthy Volunteers

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
Samsung Medical Center

Completed

The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients (CPPCI)

Adherence, Medication | Percutaneous Coronary Intervention | Compliance, Medication | Platelet Aggregation Inhibitors | Hydroxymethylglutaryl-coa Reductase Inhibitors | Persistence, Medication

Korea, Republic of
R-Pharm

Completed

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Breast Cancer | Metastases

United States, Netherlands, Argentina, Canada, South Africa, Mexico, Norway, Sweden, France, Germany
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Bristol-Myers Squibb

Completed

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Bristol-Myers Squibb

Completed

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Solid Tumor

China
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)

Renal Cell Carcinoma

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Nektar Therapeutics

Completed

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Advanced Cancer

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Resectable Biliary Tract Cancer
National Cancer Institute (NCI)

Terminated

Ixabepilone to Treat Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Carcinoma | Cervical Carcinoma, Non-SquamousType

United States
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Non-small Cell Lung Cancer

United States
The Netherlands Cancer Institute

Completed

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (IMCISION)

Head and Neck Neoplasms | Immunotherapy

Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Bristol-Myers Squibb

Withdrawn

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (PD-L1)

Stage III or IV Melanoma
BeiGene

Recruiting

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Advanced Solid Tumors

United States, Australia, Spain
University of Valencia

Completed

Efficacy of Different Versions of the Best Possible Self Intervention

General Population

Spain
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Bristol-Myers Squibb

Completed

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

CANCER, NOS

United States

Search clinical trials for: BMS-708163

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations